
    
      Subjects will be assigned to receive either Besivance or Vigamox (1:1) to be administered as
      1 drop in the study eye 4 times daily starting 3 days prior to cataract surgery and
      continuing for 7 days post-operatively.

      Sixty subjects (30 from Ophthalmology Consultants and 30 from Ophthalmology Associates) of
      any race and either sex, requiring cataract extraction with planned implantation of a
      posterior chamber intraocular lens.
    
  